Life After Wegovy: What the Evidence Says About Stopping Treatment

The withdrawal trial findings, and why regain is biological not personal

The clearest evidence comes from the STEP 1 extension study. After 68 weeks on semaglutide 2.4mg, participants had lost an average of around 15% of their body weight. Those who then switched to placebo for a further 52 weeks regained roughly two-thirds of that within the year. By week 120, body weight, waist circumference, blood pressure and blood-sugar markers had all moved substantially back toward baseline. Participants who stayed on the medicine kept their losses.

This is not a surprise to the researchers or to prescribers who follow the evidence. Semaglutide works partly by mimicking a gut hormone that signals fullness and slows gastric emptying. When the medicine leaves your system, those signals quieten. Appetite returns, often feeling stronger than it did before treatment. The NHS patient information for semaglutide is clear that weight management with Wegovy is intended as a sustained programme alongside diet and activity changes, not a short fixed course.

Understanding this biology changes how you approach stopping. It is not a personal failing if weight starts returning. It is the expected pharmacology, and it is a reason to have a proper clinical conversation before stopping rather than after.

What the NICE recommendation means for how long you can stay on Wegovy

NICE recommends semaglutide 2.4mg for weight management for a maximum of two years, used within a specialist weight management service that includes multidisciplinary support. That recommendation, set out in NICE technology appraisal TA875, also advises reviewing whether to continue at six months: if someone has not lost at least 5% of their starting weight by then on the maintenance dose, continuing may not be appropriate.

Two years is the frame NICE assessed the evidence against, not a statement that the medicine stops working at that point. For people accessing Wegovy privately, the clinical picture is considered individually. Some people remain on treatment beyond that window, others choose to step down earlier. What matters is that the decision is made with a prescriber who knows your health history, not assumed or unilateral.

Questions about long-term treatment are ones many people on Wegovy ask, and there is no single right answer. The evidence does suggest that people who have used Wegovy successfully and then stopped are not in the same position as someone who never started: the habits, the relationship with food, and sometimes the metabolic changes built during treatment can still matter after stopping.

Practical steps that make a real difference after you stop

No lifestyle intervention fully replaces the medicine, and it would be misleading to suggest otherwise. But what you do in the period after stopping has been shown to influence the rate and extent of regain. Keeping a higher protein intake helps preserve muscle mass, which matters for metabolism. Regular resistance exercise, even modest amounts, slows the return of fat mass. Staying connected to a healthcare team, rather than disappearing quietly, means problems are caught early.

The practical side of stopping Wegovy is worth planning before your last pen, not after. Storage and pen shelf life are separate considerations if you are pausing rather than stopping entirely; the guidance on open pen storage is worth reading if you are thinking about a break. And if cost has been a factor in the decision to stop, it is worth looking at what is genuinely included in private Wegovy pricing before assuming you cannot afford to continue.

Some people find that stopping Wegovy prompts a broader conversation about weight as a long-term health condition rather than a problem to be fixed once. That reframe matters. The NHS obesity treatment page outlines the range of approaches available and the evidence behind them, which is a useful starting point if you and your prescriber are mapping what comes next.

Whether restarting is an option, and what that involves clinically

Restarting Wegovy after a gap is possible, but it is not simply a case of picking up where you left off. Prescribers generally restart from a lower dose to allow your body to readjust, working back up through the titration schedule. How long you were off the medicine and what changed in your health in the meantime both affect the assessment.

The question of whether you might be on Wegovy for life is one more people are asking as the long-term evidence accumulates. Taking semaglutide long-term is a live area of research and clinical practice, and what is appropriate varies person to person. A consultation is the right place to weigh your options. If you would like to speak to a prescriber about what stopping, pausing or restarting might mean for you, our team is here seven days a week.

At nume, a real clinician reads your consultation the same day and can help you think through the next step. If that sounds useful, speaking to our prescribers is straightforward and free to start.